» Articles » PMID: 12842902

Human Combinatorial Fab Library Yielding Specific and Functional Antibodies Against the Human Fibroblast Growth Factor Receptor 3

Abstract

The human combinatorial antibody library Fab 1 (HuCAL-Fab 1) was generated by transferring the heavy and light chain variable regions from the previously constructed single-chain Fv library (Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wölle, J., Plückthun, A., and Virnekäs, B. (2000) J. Mol. Biol. 296, 57-86), diversified in both complementarity-determining regions 3 into a novel Fab display vector, yielding 2.1 x 10(10) different antibody fragments. The modularity has been retained in the Fab display and screening plasmids, ensuring rapid conversion into various antibody formats as well as antibody optimization using prebuilt maturation cassettes. HuCAL-Fab 1 was challenged against the human fibroblast growth factor receptor 3, a potential therapeutic antibody target, against which, to the best of our knowledge, no functional antibodies could be generated so far. A unique screening mode was designed utilizing recombinant functional proteins and cell lines differentially expressing fibroblast growth factor receptor isoforms diversified in expression and receptor dependence. Specific Fab fragments with subnanomolar affinities were isolated by selection without any maturation steps as determined by fluorescence flow cytometry. Some of the selected Fab fragments completely inhibit target-mediated cell proliferation, rendering them the first monoclonal antibodies against fibroblast growth factor receptors having significant function blocking activity. This study validates HuCAL-Fab 1 as a valuable source for the generation of target-specific antibodies for therapeutic applications.

Citing Articles

A Strategy for Simultaneous Engineering of Interspecies Cross-Reactivity, Thermostability, and Expression of a Bispecific 5T4 x CD3 DART Molecule for Treatment of Solid Tumors.

Huang R, Spliedt M, Kaufman T, Gorlatov S, Barat B, Shah K Antibodies (Basel). 2025; 14(1.

PMID: 39846615 PMC: 11755548. DOI: 10.3390/antib14010007.


Production of an Efficient Enzymatically Fab Fragment Antivenom against Cobra Snake () Venom.

Motedayen M, Zolfagharian H Arch Razi Inst. 2024; 79(2):411-417.

PMID: 39463715 PMC: 11512180. DOI: 10.32592/ARI.2024.79.2.411.


Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.

Cummings J, Leisgang Osse A, Cammann D, Powell J, Chen J BioDrugs. 2023; 38(1):5-22.

PMID: 37955845 PMC: 10789674. DOI: 10.1007/s40259-023-00633-2.


Epivolve: A Protocol for Site-Directed Antibodies.

Li X, Jones K, Acca F, Chapados C, Driscoll H, Fuller E Methods Mol Biol. 2023; 2702:587-601.

PMID: 37679640 PMC: 10568616. DOI: 10.1007/978-1-0716-3381-6_29.


Targeting Intracellular Antigens with pMHC-Binding Antibodies: A Phage Display Approach.

Yang Z, Wu Z, Santich B, Liu J, Liu C, Cheung N Methods Mol Biol. 2023; 2702:327-345.

PMID: 37679628 DOI: 10.1007/978-1-0716-3381-6_17.